Literature DB >> 17881449

Association of Nef with p21-activated kinase 2 is dispensable for efficient human immunodeficiency virus type 1 replication and cytopathicity in ex vivo-infected human lymphoid tissue.

Michael Schindler1, Devi Rajan, Anke Specht, Carolin Ritter, Kati Pulkkinen, Kalle Saksela, Frank Kirchhoff.   

Abstract

Interaction of the human immunodeficiency virus type 1 (HIV-1) Nef protein with p21-activated kinase 2 (PAK2) has been proposed to play a role in T-cell activation, viral replication, apoptosis, and progression to AIDS. However, these hypotheses were based on results obtained using Nef mutants impaired in multiple functions. Recently, it was reported that Nef residue F191 is specifically involved in PAK2 binding. However, only a limited number of Nef activities were investigated in these studies. To further evaluate the role of F191 in Nef function and to elucidate the biological relevance of Nef-PAK2 interaction, we performed a comprehensive analysis of HIV-1 Nef mutants carrying F191H and F191R mutations. We found that the F191H mutation reduces and the F191R mutation disrupts the association of Nef with PAK2. Both mutants upregulated the major histocompatibility complex II (MHC-II)-associated invariant chain and downregulated CD4, MHC-I, and CD28, although with reduced efficiency for the latter. Furthermore, the F191H/R changes neither affected the levels of interleukin-2 receptor expression and apoptosis of HIV-1-infected primary T cells nor reduced Nef-mediated induction of NFAT. Unexpectedly, the F191H change markedly reduced and the F191R mutation disrupted the ability of Nef to enhance virion infectivity in P4-CCR5 indicator cells but not in TZM-bl cells or peripheral blood mononuclear cells. Most importantly, all HIV-1 Nef mutants replicated efficiently and caused CD4+ T-cell depletion in ex vivo-infected human lymphoid tissue. Altogether, our data show that the interaction of Nef with PAK2 does not play a major role in T-cell activation, viral replication, and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17881449      PMCID: PMC2169106          DOI: 10.1128/JVI.01436-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  83 in total

Review 1.  HIV accessory proteins and surviving the host cell.

Authors:  Jenny L Anderson; Thomas J Hope
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

2.  Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef.

Authors:  Eduardo O'Neill; Lillian S Kuo; John F Krisko; Diana R Tomchick; J Victor Garcia; John L Foster
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1.

Authors:  Michael Schindler; Jan Münch; Olaf Kutsch; Hui Li; Mario L Santiago; Frederic Bibollet-Ruche; Michaela C Müller-Trutwin; Francis J Novembre; Martine Peeters; Valerie Courgnaud; Elizabeth Bailes; Pierre Roques; Donald L Sodora; Guido Silvestri; Paul M Sharp; Beatrice H Hahn; Frank Kirchhoff
Journal:  Cell       Date:  2006-06-16       Impact factor: 41.582

4.  A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Primary sooty mangabey simian immunodeficiency virus and human immunodeficiency virus type 2 nef alleles modulate cell surface expression of various human receptors and enhance viral infectivity and replication.

Authors:  Jan Münch; Michael Schindler; Steffen Wildum; Elke Rücker; Nicola Bailer; Volker Knoop; Francis J Novembre; Frank Kirchhoff
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Selective restriction of Nef-defective human immunodeficiency virus type 1 by a proteasome-dependent mechanism.

Authors:  Mingli Qi; Christopher Aiken
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

7.  CD4 down-modulation by human immunodeficiency virus type 1 Nef correlates with the efficiency of viral replication and with CD4(+) T-cell depletion in human lymphoid tissue ex vivo.

Authors:  S Glushakova; J Münch; S Carl; T C Greenough; J L Sullivan; L Margolis; F Kirchhoff
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

8.  Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques.

Authors:  J Münch; N Stolte; D Fuchs; C Stahl-Hennig; F Kirchhoff
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Importance of the N-distal AP-2 binding element in Nef for simian immunodeficiency virus replication and pathogenicity in rhesus macaques.

Authors:  Matthias Brenner; Jan Münch; Michael Schindler; Steffen Wildum; Nicole Stolte; Christiane Stahl-Hennig; Dietmar Fuchs; Kerstin Mätz-Rensing; Monika Franz; Jonathan Heeney; Peter Ten Haaft; Tomek Swigut; Katarzyna Hrecka; Jacek Skowronski; Frank Kirchhoff
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

10.  The role of upstream U3 sequences in HIV-1 replication and CD4+ T cell depletion in human lymphoid tissue ex vivo.

Authors:  Jan Münch; Devi Rajan; Elke Rücker; Steffen Wildum; Nadia Adam; Frank Kirchhoff
Journal:  Virology       Date:  2005-08-15       Impact factor: 3.616

View more
  17 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

3.  HIV-1 Nef interferes with T-lymphocyte circulation through confined environments in vivo.

Authors:  Bettina Stolp; Andrea Imle; Fernanda Matos Coelho; Miroslav Hons; Roser Gorina; Ruth Lyck; Jens V Stein; Oliver T Fackler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-23       Impact factor: 11.205

4.  Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function.

Authors:  Michael O Alberti; Jennifer J Jones; Riccardo Miglietta; Haitao Ding; Rakesh K Bakshi; Tara G Edmonds; John C Kappes; Christina Ochsenbauer
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-23       Impact factor: 2.205

5.  Lentiviral Nef proteins utilize PAK2-mediated deregulation of cofilin as a general strategy to interfere with actin remodeling.

Authors:  Bettina Stolp; Libin Abraham; Jochen M Rudolph; Oliver T Fackler
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

Review 6.  Mechanisms of HIV-1 Nef function and intracellular signaling.

Authors:  John L Foster; Sarah J Denial; Brenda R S Temple; J Victor Garcia
Journal:  J Neuroimmune Pharmacol       Date:  2011-02-19       Impact factor: 4.147

7.  Function of ubiquitin (Ub) specific protease 15 (USP15) in HIV-1 replication and viral protein degradation.

Authors:  Dohun Pyeon; Khalid Amine Timani; Fahad Gulraiz; Johnny J He; In-Woo Park
Journal:  Virus Res       Date:  2016-07-25       Impact factor: 3.303

Review 8.  An emerging role for p21-activated kinases (Paks) in viral infections.

Authors:  Celine Van den Broeke; Maria Radu; Jonathan Chernoff; Herman W Favoreel
Journal:  Trends Cell Biol       Date:  2010-01-12       Impact factor: 20.808

Review 9.  How HIV takes advantage of the cytoskeleton in entry and replication.

Authors:  Bettina Stolp; Oliver T Fackler
Journal:  Viruses       Date:  2011-03-28       Impact factor: 5.048

10.  Nef-mediated enhancement of cellular activation and human immunodeficiency virus type 1 replication in primary T cells is dependent on association with p21-activated kinase 2.

Authors:  Kevin C Olivieri; Joya Mukerji; Dana Gabuzda
Journal:  Retrovirology       Date:  2011-08-05       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.